Clinical TrialsPromising results from the GLP-1-H25-5 study indicate that oral DehydraTECH-liraglutide could deliver comparable functional results with reduced adverse events compared to injected liraglutide.
Partnership OpportunitiesLexaria is now searching for a pharmaceutical partner to advance the clinical program for DehydraTECH-liraglutide, which could lead to significant developments in its clinical pathway.
Regulatory ApprovalsHuman pilot study #5 receives approval to proceed.
Side EffectsA 22.7% reduction in adverse events was observed with oral DehydraTECH-liraglutide compared to injected Saxenda, including a 67% reduction in nausea.